Clinical Trials Logo

Hepatitis A clinical trials

View clinical trials related to Hepatitis A.

Filter by:

NCT ID: NCT04781647 Terminated - Chronic Hepatitis B Clinical Trials

A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B Virus Infection

Start date: February 18, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, antiviral activity, and pharmacokinetics of ABI-H0731 in combination with entecavir (ETV) and with ETV plus pegylated-interferon alpha (Peg-IFNα) in Chinese participants with chronic hepatitis B virus infection (cHBV)

NCT ID: NCT04684914 Terminated - Clinical trials for Hepatitis B, Chronic

HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)

Start date: December 26, 2020
Phase: Phase 2
Study type: Interventional

A study to evaluate the antiviral effects, immunogenicity, and safety of HepTcell in treatment-naive patients with inactive Chronic Hepatitis B (CHB) and low Hepatitis B surface antigen (HBsAg) levels.

NCT ID: NCT04499651 Terminated - Hepatitis C Clinical Trials

Testing of a Navigation Intervention for Hepatitis C and HIV

LINKHCV
Start date: July 31, 2020
Phase: N/A
Study type: Interventional

This study will evaluate the efficacy of navigation for hepatitis C treatment in people living with both HIV and HCV with criminal justice involvement.

NCT ID: NCT04454567 Terminated - Chronic Hepatitis B Clinical Trials

A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors

Start date: November 11, 2020
Phase: Phase 2
Study type: Interventional

This study will explore the safety and antiviral activity of ABI-H0731 when added to a nucleos(t)ide reverse transcriptase inhibitor (NrtI) in participants who are partially virologically suppressed.

NCT ID: NCT04398134 Terminated - Chronic Hepatitis B Clinical Trials

A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection

Start date: August 28, 2020
Phase: Phase 2
Study type: Interventional

This Phase 2a study will assess the safety, antiviral activity, and pharmacokinetics (PK) of ABI-H2158 administered once daily for up to 72 weeks in combination with entecavir (ETV) in participants with chronic hepatitis B virus (HBV) infection.

NCT ID: NCT04356404 Terminated - Immunosuppression Clinical Trials

Risk of Hepatitis Flare in Patients With Previous Hepatitis B Virus Exposure Amongst Patients

Start date: May 1, 2020
Phase:
Study type: Observational

The purpose of this study is to study the risk of hepatitis flare in patients with previous hepatitis B virus exposure amongst patients on immunosuppressive and biological modifier therapies

NCT ID: NCT04203875 Terminated - Clinical trials for Autoimmune Hepatitis

Abatacept for Treatment of Recurrent or de Novo Autoimmune Hepatitis

Start date: March 9, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate whether Orencia® (Abatacept) improves outcomes in liver transplant patients with recurrent or de novo AIH (autoimmune hepatitis) that has not responded to previous therapy. AIH that does not respond to steroids or conventional immunotherapy often affects young patients and leads to irreversible liver damage. There is currently no effective therapy for this condition.

NCT ID: NCT04129489 Terminated - Clinical trials for Autoimmune Hepatitis

A Phase 2a Study to Evaluate the Safety and Efficacy of Cannabidiol Only as Maintenance Therapy and Steroid Sparing in Patients With Stable Autoimmune Hepatitis

Start date: February 7, 2019
Phase: Phase 2
Study type: Interventional

Subjects with stable autoimmune hepatitis disease currently being administered corticosteroids with or without azathioprine (AZA) treatment will be be treated with Cannabidiol instead of standard of care treatment with corticosteroids

NCT ID: NCT04059198 Terminated - Hepatitis B Clinical Trials

Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus

Start date: October 10, 2019
Phase: Phase 2
Study type: Interventional

An open-label, Phase 2, exploratory study to examine the safety and efficacy of inarigivir in non-cirrhotic, hepatitis B treatment-naive subjects with chronic HBV infection.

NCT ID: NCT04057001 Terminated - Hepatitis C Clinical Trials

Hepatitis C Positive Organ to Recipient Hepatitis C Negative Longitudinal Transplant Study

HERCULES
Start date: July 1, 2019
Phase:
Study type: Observational

Compare wait list mortality and time to liver, heart or kidney transplant for registrants listed to consider allografts from Hepatitis C Virus (HCV) Nucleic Amplification Testing (NAT)+ donors versus those who are not . The umbrella protocol has been set up to include heart and kidney transplant recipients.